Talk:Acelity

Untitled
I am submitting a new article for consideration about Acelity. The draft was rejected as it was viewed as promotional and not from a neutral point of view. I am familiar with this organization and should state at the outset that I may be viewed as having a conflict of interest; however, I have read the WP:COI and WP:NPOV policies and wish to make it clear that my only interest is in reporting the facts accurately. I hope that other users will offer suggestions and guidance during this process. In fact, I consulted with editors using the LiveChat feature and based on their advice, I re-wrote the article instead of making edits to the draft. This is my first foray into WIkipedia and I very much look forward to becoming an entrenched and contributing member of the community. Any feedback you have is appreciated. Thanks. Bonsecour (talk) 22:53, 2 December 2014 (UTC)

Updates to Acelity Page
My name is Laurel Harper, and I am reaching out on behalf of the Corporate Communications team at Acelity.

I'm reaching out because we have some additional and more recent information about the company that we think would be relevant for the Acelity wiki, and wanted to make sure we reached out to submit this information for consideration and talk through any of these points as needed. I have a draft with cited sources that I can email.

Many thanks in advance for your help!

All best, LEHarper2016 (talk) 16:08, 31 May 2016 (UTC)Laurel

@LEHarper2016: It would be better if your draft could be posted at the article's talk page, Talk:Acelity, so that it could be reviewed by any editors there. Trying to do reviews by email would probably be pretty painful, and it's preferred that any such would be done publicly. Seraphimblade Talk to me 19:51, 31 May 2016 (UTC)

Hello, per Seraphimblade's recommendation copied above, I am posting the revised draft of the Acelity page here for consideration to update the Acelity page with company facts and recent news. Please advise on next steps and thank you in advance for your assistance.

Acelity Acelity L.P. Inc., is a privately held medical device company. It is a non-operating holding company whose wholly owned subsidiaries develop advanced wound therapeutics and regenerative medicine products. The advanced wound therapeutics business is conducted by Kinetic Concepts, Inc. (KCI) and its subsidiaries, including Systagenix, and the regenerative medicine business is conducted by LifeCell.[1]

Acelity's products are available in more than 80 countries. The company employs more than 5,800 people around the world. The company reported $1.87 billion in annual revenue globally in 2015.[|2]

History KCI: Acelity began as KCI, a medical technology company founded in 1976 by Dr. Jim Leininger, an emergency room physician in [|San Antonio], [|Texas].3 Over time, the company developed or acquired a line of [|therapeutic specialty beds], introducing a specialty bed for acute care patients with pulmonary complications.[|4]

Initially KCI's product development focused on therapeutic beds and surfaces and then expanded to introduce V.A.C.® Therapy, the first commercial [|negative pressure wound therapy] product in the mid-1990s.[|5][|6] In a study [http://www.woundsresearch.com/article/comparison-health-care-costs-andhospital-readmission-rates-associated-negative-pressure. published in WOUNDS] in 201212, patients treated with V.A.C.® Therapy were associated with lower total costs, lower wound-related costs and lower hospital readmission rates than other negative pressure wound therapy patients. In 2016, more than 10 million wounds13 have been treated with V.A.C.® Therapy worldwide.

LifeCell: In 2008, KCI acquired LifeCell, a company specializing in regenerative medicine, in a non-hostile transaction for US$1.7 billion.[|7][|8]9

Systagenix: In October 2013, KCI acquired Systagenix Wound Management, formerly Johnson & Johnson's professional wound care business for $485 million.[|10]

Acelity: In September 2014, KCI's parent company announced that KCI, LifeCell and Sytagenix would operate under one global medical technology brand known as Acelity.[|11]

Financial Information From the founding of KCI in 1976 to 1988, the revenue of KCI grew to US$153.2 million. The growth in revenue allowed KCI to [|go public] and trade on the [|New York Stock Exchange] (NYSE) for the first time in 1988[|26]. KCI stock was traded on the NYSE until 1997, when the company went private. In February 2004, KCI became a publicly listed company for the second time and was listed on the NYSE under the ticker symbol KCI[|27][|28]. By the late 2000s, the company’s revenue was over $1 billion and reported an increase of 17 percent in 2007 to 1.61 billion[|29]. Revenue for 2008 was $1.88 billion, increasing to $1.99 billion in 200930 and in 2010 increased to $2.02 billion[|31]. In 2011, KCI was acquired in a leveraged buyout for $4.98 billion in cash by the APAX-led consortium32. On November 4, 2011, the company went private again at a price of $68.50 per share. In August 2015, Acelity filed a registration statement on Form S-1 with the US Securities and Exchange Commission relating to a proposed initial public offering of its common stock33.

Operations Acelity serves its product portfolio in 80 countries and is focused in two business segments: Advanced Wound Therapeutics: This business segment develops and commercializes advanced devices from KCI and advanced wound dressings from Systagenix, including [|negative pressure wound therapy], negative pressure surgical management and epidermal harvesting. [|Regenerative Medicine:] The development and commercialization of regenerative and reconstructive acellular tissue matrices from LifeCell for use in [|general] and reconstructive surgical procedures to repair soft tissue defects and autologous fat grafting solutions.

Products Advanced Wound Therapy key products: • V.A.C.® Negative Pressure Wound Therapy Systems14: Negative pressure technology substantiated by more than 45 randomized controlled clinical trials and over 1,000 peer-reviewed articles • PREVENA™ Incision Management System15: The first powered negative pressure system designed specifically for the management of closed surgical incisions that continue to drain following sutured or stapled closure • CELLUTOME™ Epidermal Harvesting System16: Intended to reproducibly harvest a thin skin graft for autologous skin grafting • ABTHERA™ Open Abdomen Negative Pressure Therapy17: Temporary abdominal closure (TAC) system designed to manage the open abdomen • PROMOGRAN™ Matrix Wound Dressing: Clinical solution for wound management, diabetic foot ulcers, venous leg ulcers and pressure ulcers • PROMOGRAN PRISMA™ Matrix: Intended for the management of exuding wounds, including diabetic, venous and pressure ulcers, abrasions, and surface wounds • TIELLE™ Family Dressings26: Range of hydropolymer foams with LIQUALOCK™ Advanced Absorption Technology designed to manage different levels of exudates across a range of wound types

Regenerative Medicine Key products: • ALLODERM SELECT™ Regenerative Tissue Matrix18: Donated human dermis, processed to remove cells while preserving biological components and structure of the dermal matrix to support regeneration • STRATTICE™ Reconstructive Tissue Matrix19: Biological mesh used in plastic surgery and abdominal wall reconstruction procedures

Product Technology Negative Pressure Wound Therapy Technology: This technology is used in the company’s V.A.C.® Therapy portfolio of products. V.A.C.® Therapy delivers negative pressure (a vacuum) at the wound site through a proprietary foam dressing, drawing the wound edges together, removing infectious materials, reducing edema and promoting granulation tissue formation. When sealed and placed under negative pressure, the dressing conforms to the wound bed. SENSAT.R.A.C.™ Technology: This is a proprietary technology that maintains and adjusts to deliver set pressure at the wound site. Products that have the SENSAT.R.A.C.™ Technology include, V.A.C.ULTA™ Therapy System, INFOV.A.C.™ Therapy System, ACTIV.A.C.™ Therapy System, V.A.C. FREEDOM™ Therapy System, V.A.C. ATS™ Therapy System, V.A.C. SIMPLICITY™ Therapy System and V.A.C.VIA™ Therapy System. Tissue Matrix Process: Acelity’s proprietary processing from LifeCell supports regeneration with ALLODERM™ and STRATTICE ™. This process maintains the structure of the extracellular matrix and collagen network, allowing the patient’s body to recognize the tissue matrix as its own. Surgeons use tissue regeneration technology for plastic and abdominal wall reconstruction. Fat Processing Technology: The REVOLVE™ System from LifeCell uses a fat processing technology and is a single-use, sterile, disposable device for harvesting, filtering and transferring autologous adipose tissue in fat grafting procedures.

Mergers & Acquisitions Early 1990s: KCI detailed its operations into four divisions21: KCI New Technologies, Inc. (Nutech—organized in 1992 focused on lower-cost technologies), KCI Home Care (organized in 1995 focused on selling wholesale to home medical equipment providers), KCI Therapeutic Services, Inc. (KCTS—rents specialty beds to patients or to hospitals), and KCI International (KCII—organized in 1991 focused on providing the services and products of KCI to foreign countries, including most of western Europe, Scandinavia, and Australia). 1990: KCI purchased Medirec20 for $26 million in cash and $10 million in KCI securities, forming KCI’s Medical Services Division. KCI later sold KCI Medical Services22 in September of 1994 for $65.3 million in cash and $18.8 million in promissory notes. 1991: KCI purchased Mediscus International, a British competitor in the specialty bed business. The transaction brought KCI products into 10 countries and formed the KCI International subsidiary. 1996: KCI purchased U.K.-based Astec Medical Ltd. 23 The acquisition added four new products to KCI International’s product line and allowed KCI to expand its market share in the U.K. community care segment. 1997: KCI acquired the Ethos Medical Group. Later that year, Equitron Manufacturing was acquired, adding bariatric products to the Home Care offerings at KCI. 1998: KCI USA was formed as a result of the merger between KCI’s New Technologies (NuTech) with KCI Therapeutic Services. The merger united the sales and marketing operations of the two divisions. 2008: KCI acquired LifeCell, a company specializing in regenerative medicine, in a non-hostile transaction for US$1.7 billion.7[|8][|9] 2012: KCI acquired MoMelan Technologies, which allowed the company to launch CELLUTOME™ Epidermal Harvesting System in 2013.34 2013: KCI acquired Systagenix Wound Management, formerly Johnson & Johnson's professional wound care business for $485 million.[|10] 2014: KCI's parent company announced that KCI, LifeCell and Sytagenix would operate under one global medical technology brand known as Acelity.[|11] Acelity acquired exclusive worldwide rights from the GID Group, Inc. to develop, manufacture and commercialize the REVOLVE™ System24, a fat processing technology used in both reconstructive and cosmetic procedures to facilitate high-volume, autologous fat grafting. LifeCell, an Acelity Company, previously held exclusive rights to distribute the REVOLVE™ System in the US and Canada since 2013. 2015: Acelity acquired the SNAP™ business from Spiracur, Inc. 25 SNAP™ is a portable, non-powered device designed to treat hard-to-heal wounds.

References 1. Acelity L.P. Inc. Form 10-Q for period ending. Sept. 2014. http://www.sec.gov/Archives/edgar/data/1557939/000155793914000071/a2014q310q.htm 2. San Antonio’s Acelity showing signs of progress. http://www.bizjournals.com/sanantonio/news/2016/01/26/san-antonio-s-acelity-showing-signs-of-progress.html 3. Kinetic Concepts Inc. Implements SolidWorks Software as Company-Wide Engineering Standard.” Business Wire. 6 March 2000 Kinetic Concepts introduces TriaDyne, latest addition to line of therapeutic beds and surfaces". Business Wire. 23 May 1995. 4. Benesh, Peter (14 June 2004). "Second IPO Helps Heal Old Wounds; Kinetic Concepts Inc.; San Antonio, Texas". Investor's Business Daily. p. A09. 5. KCI Honors Dr. Louis Argenta With Research-Based Fellowship and Scholarship". Business Wire. 12 October 2009. 6. KCI earnings up during second quarter". http://www.bizjournals.com/sanantonio/stories/2009/07/20/daily9.html?s=industry&i=health_care San Antonio Business Journal. 21 July 2009. Retrieved 25 January 2011. 7. KCI to Acquire LifeCell for $1.7 Billion in Cash Creating a Global Medical Technology Leader". Business Wire. 7 April 2008. 8. Analyst questions Kinetic Concepts' purchase of LifeCell due to high price and low revenue". The Associated Press. 8 April 2008. 9. KCI buying Systagenix for $485M. http://www.mysanantonio.com/business/local/article/KCI-buying-Systagenix-for-485M-4695250.php. San Antonio Express-News. 30 July 2013 10. KCI parent company remaking itself as Acelity". http://www.bizjournals.com/sanantonio/news/2014/09/03/kci-parent-company-remaking-itself-as-acelity.html San Antonio Business Journal. 3 September 2014. 11. Comparison of Health Care Costs and Hospital Readmission Rates Associated With Negative Pressure Wound Therapies. http://www.woundsresearch.com/article/comparison-health-care-costs-and-hospital-readmission-rates-associated-negative-pressure. Wounds: A Compendium of Clinical Research and Practice. 11 March 2015. 12. How KCI became an industry giant. http://www.expressnews.com/150years/education-health/article/KCI-becomes-San-Antonio-s-largest-medical-6379609.php. San Antonio Express News. 11 July 2015. 13. V.A.C.® Therapy Clinical Evidence. http://www.acelity.com/cs/Satellitec=Page&cid=1440430466170&childpagename=Acelity/Page/Libraries_Template&pagename=WrapperEntry&articleid=1440439018749. PubMed Abstracts. 14. PREVENA™ Incision Management System Clinical Evidence. http://www.acelity.com/cs/Satellitec=Page&cid=1440430466170&childpagename=Acelity/Page/Libraries_Template&pagename=WrapperEntry&articleid=1440439018526. PubMed Abstracts. 15. Epidermal grafting using a novel suction blister-harvesting system for the treatment of pyoderma gangrenosum. http://www.ncbi.nlm.nih.gov/pubmed/25104506. PubMed Abstract. 2014 September. 16. ABTHERA™ Therapy Clinical Evidence. http://www.acelity.com/cs/Satellitec=Page&cid=1440430466170&childpagename=Acelity/Page/Libraries_Template&pagename=WrapperEntry&articleid=1440438945799. PubMed Abstracts. 17. ALLODERM™ Regenerative Tissue Matrix Clinical Evidence. http://www.acelity.com/cs/Satellitec=Page&cid=1440430466170&childpagename=Acelity/Page/Libraries_Template&pagename=WrapperEntry&articleid=1440438947467. PubMed Abstracts. 18. STRATTICE™ Regenerative Tissue Matrix Clinical Evidence. http://www.acelity.com/cs/Satellitec=Page&cid=1440430466170&childpagename=Acelity/Page/Libraries_Template&pagename=WrapperEntry&articleid=1440439018716. PubMed Abstracts. 19. Texas Firm Acquires Medirec. http://www.deseretnews.com/article/115704/TEXAS-FIRM-ACQUIRES-MEDIREC.html?pg=all. Deseret News. 5 August 1990. 20. Company Histories, Kinetic Concepts, Inc. (KCI). http://www.company-histories.com/Kinetic-Concepts-Inc-KCI-Company-History.html. 21. KCI shopping the market for right acquisition opportunity. http://www.bizjournals.com/sanantonio/stories/1996/06/24/story8.html?page=3. San Antonio Business Journal. 23 June 1996. 23. Kinetic Concepts Inc 10-K. http://www.secinfo.com/dPCEg.8a.a.htm. 31 December 1996. 23. Acelity Scoops Up Worldwide Rights for REVOLVE Fat Grafting System. http://www.plasticsurgerypractice.com/2014/11/acelity-now-owns-exclusive-worldwide-right-revolve-fat-processing-system/. Plastic Surgery Practice. 20 November 2014. 24. Acelity acquires wound-care technology from California company. http://www.bizjournals.com/sanantonio/news/2015/12/01/acelity-acquires-wound-care-technology-from.html. San Antonio Business Journal. 1 December 2015. 25. Acelity CEO: SA biotech firm’s U.S. product launch part of bigger global plan. http://www.bizjournals.com/sanantonio/news/2016/04/18/acelity-ceo-sa-bioetech-firms-u-s-product-launch.html. San Antonio Business Journal. 18 April 2016. 26. Blaker, Ashley (24 December 1990). "Kinetic Expands Foreign Presence With Acquisitions". San Antonio Business Journal 4 (49): 1. 27. Benesh, Peter (14 June 2004). "Second IPO Helps Heal Old Wounds; Kinetic Concepts Inc.; San Antonio, Texas". Investor's Business Daily. p. A09. 28. Berko, Malcolm (3 August 2007). "Wound-care developer is a healthy company". Copley News Service. 29. "KCI concludes 2007 on strong note". San Antonio Business Journal. 29 January 2008. 30. "Highlights KCI". MSN Money. MSN. January 2011. Retrieved 25 January 2011. 31. "Kinetic Concepts 4Q profit grows 12 percent". Bloomberg Business News. Associated Press. 1 February 2011. Retrieved 4 February 2011. 32. Kinetic Agrees to $4.98 Billion Acquisition By Apax Group. http://www.bloomberg.com/news/articles/2011-07-13/kinetic-concepts-agrees-to-be-acquired-for-68-50-a-share-1-. Bloomberg. 13 July 2011 33. Acelity Aims for Massive IPO. http://247wallst.com/healthcare-business/2015/10/08/acelity-aims-for-massive-ipo/. 24/7 Wall Street. 8 October 2015 34. MoMelan Technologies Stealthily Acquired by Kinetic Concepts. http://www.xconomy.com/boston/2012/11/16/momelan-technologies-stealthily-acquired-by-kinetic-concepts/#. Xconomy. 16 November 2012.

Sidebar with Acelity logo Type: Non-operating holding company Industry: Medical equipment Founded: 1976; 40 years ago Headquarters: San Antonio, Texas Key people: Joe Woody (CEO) Revenue: $1.87 billion (2015) Gross Profit: $1.25 billion (2015) Operating Earnings: $363.3 million (2015) Net Loss: $47.7 million (2015) Number of employees: 5,800 (2015) Website: www.acelity.com

LEHarper2016 (talk) 15:42, 23 June 2016 (UTC)Laurel Harper

products & technologies
moved here per PRESERVE. needs independent sourcing; as it stands now, fails WP:PROMO

V.A.C. Negative Pressure Wound Therapy Systems: Negative pressure technology substantiated by more than 45 randomized controlled clinical trials and over 1,000 peer-reviewed articles
 * Products & Technologies

V.A.C.ULTA Negative Pressure Wound Therapy System with V.A.C. VERAFLO Instillation Therapy: Next generation wound therapy system enabled for topical wound solution instillation

SENSAT.R.A.C. Technology: Feedback sensing technology to ensure that selected negative pressure is accurately delivered at the wound site

PREVENA Incision Management System: The first powered negative pressure system designed specifically for the management of closed surgical incisions that continue to drain following sutured or stapled closure

CELLUTOME Epidermal Harvesting System: Intended to reproducibly harvest a thin skin graft for autologous skin grafting

ALLODERM Regenerative Tissue Matrix: Human acellular dermal tissues

STRATTICE Regenerative Tissue Matrix: Porcine acellular dermal tissues

REVOLVE System High-volume autologous fat grafting system to deliver rapid and reliable adipose tissue processing

PROMOGRAN Matrix Wound Dressing and PROMOGRAN PRISMA Matrix Dressing: Specialist dressings that help maintain a most wound environment conducive to wound healing

-- Jytdog (talk) 17:00, 5 January 2017 (UTC)

unsourced Operations section
unsourced and needs independent sourcing. Moved here per PRESERVE.

Acelity serves its product portfolio in 80 countries and is focused in two business segments:

Advanced Wound Therapeutics: This business segment develops and commercializes advanced devices from KCI and advanced wound dressings from Systagenix, including negative pressure wound therapy, negative pressure surgical management and epidermal harvesting.

Regenerative Medicine: This business segment researches and develops regenerative and reconstructive acellular tissue matrices from LifeCell for use in general and reconstructive surgical procedures, including abdominal wall and breast reconstruction procedures.

-- Jytdog (talk) 17:02, 5 January 2017 (UTC)